MediciNova, Inc.
Index- P/E- EPS (ttm)-0.27 Insider Own3.01% Shs Outstand49.04M Perf Week-5.34%
Market Cap124.60M Forward P/E- EPS next Y-37.00 Insider Trans0.00% Shs Float47.57M Perf Month3.33%
Income-13.30M PEG- EPS next Q- Inst Own14.60% Short Float2.60% Perf Quarter-4.62%
Sales4.04M P/S30.86 EPS this Y33.10% Inst Trans-6.31% Short Ratio29.67 Perf Half Y-7.46%
Book/sh1.64 P/B1.51 EPS next Y-5.10% ROA-14.90% Target Price14.25 Perf Year-39.66%
Cash/sh1.35 P/C1.84 EPS next 5Y- ROE-15.70% 52W Range2.09 - 4.65 Perf YTD-7.46%
Dividend- P/FCF- EPS past 5Y8.70% ROI-12.20% 52W High-46.67% Beta1.07
Dividend %- Quick Ratio23.10 Sales past 5Y- Gross Margin- 52W Low18.66% ATR0.11
Employees11 Current Ratio23.10 Sales Q/Q- Oper. Margin- RSI (14)46.88 Volatility4.42% 4.52%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.64 Prev Close2.47
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume41.72K Price2.48
Recom- SMA20-1.02% SMA50-1.65% SMA200-13.39% Volume27,018 Change0.40%
Mar-10-21Initiated Maxim Group Buy $15
Mar-25-19Resumed B. Riley FBR Buy $22
Mar-28-18Initiated B. Riley FBR, Inc. Buy $22
Apr-18-17Initiated Credit Suisse Outperform
Jan-04-13Reiterated Ladenburg Thalmann Buy $10.50 → $6
May-24-12Downgrade MLV & Co Buy → Hold
Oct-18-11Reiterated MLV Capital Buy $13 → $6
Jun-22-11Initiated Global Hunter Securities Buy $4
May-12-10Initiated Wedbush Outperform $13
Nov-12-08Reiterated Ladenburg Thalmann Buy $22 → $6
May-15-08Initiated Rodman & Renshaw Mkt Outperform $9
Jul-09-07Initiated Punk, Ziegel & Co Buy $22
Jun-29-22 07:00PM  
Jun-22-22 07:00PM  
Jun-13-22 06:35AM  
Jun-08-22 09:05AM  
May-25-22 06:10AM  
May-06-22 09:48AM  
Apr-21-22 07:00PM  
Apr-20-22 07:00PM  
Apr-12-22 11:00PM  
Apr-11-22 06:30AM  
Apr-08-22 09:38AM  
Apr-07-22 07:00PM  
Apr-06-22 11:15AM  
Mar-17-22 06:30AM  
Mar-15-22 06:30AM  
Mar-01-22 05:20AM  
Feb-28-22 06:30AM  
Feb-22-22 06:30AM  
Feb-14-22 01:12PM  
Feb-01-22 06:30AM  
Jan-31-22 06:30AM  
Jan-27-22 06:30AM  
Jan-26-22 06:30AM  
Dec-13-21 06:30AM  
Dec-10-21 06:30AM  
Nov-23-21 05:04AM  
Nov-22-21 06:30AM  
Nov-15-21 12:40PM  
Nov-11-21 06:00PM  
Nov-10-21 06:00PM  
Nov-03-21 07:30PM  
Oct-21-21 06:30AM  
Sep-02-21 11:00PM  
Sep-01-21 06:30AM  
Aug-30-21 06:30AM  
Aug-16-21 11:23AM  
Aug-12-21 07:00PM  
Jul-06-21 06:30AM  
Jun-29-21 06:30AM  
Jun-28-21 08:37AM  
Jun-26-21 07:34AM  
Jun-22-21 06:07AM  
Jun-21-21 06:30AM  
Jun-18-21 03:23PM  
Jun-14-21 06:30AM  
Jun-07-21 06:30AM  
May-28-21 06:25AM  
May-17-21 09:04AM  
May-13-21 04:30PM  
May-05-21 08:00PM  
Apr-26-21 05:45AM  
Apr-22-21 06:30AM  
Apr-20-21 10:51AM  
Apr-19-21 06:30AM  
Apr-15-21 06:30AM  
Mar-15-21 05:35AM  
Mar-10-21 05:25PM  
Mar-09-21 04:00PM  
Mar-08-21 06:30AM  
Mar-03-21 07:46AM  
Jan-31-21 06:00PM  
Jan-25-21 05:45AM  
Jan-18-21 06:00PM  
Jan-11-21 09:30PM  
Dec-29-20 06:30AM  
Dec-15-20 06:30AM  
Nov-30-20 05:38PM  
Nov-25-20 06:30AM  
Nov-24-20 06:30AM  
Nov-12-20 10:00PM  
Oct-30-20 06:05AM  
Oct-26-20 11:47AM  
Oct-22-20 06:30AM  
Oct-21-20 06:30AM  
Oct-13-20 06:30AM  
Sep-24-20 09:24AM  
Sep-23-20 10:37AM  
Sep-11-20 06:30AM  
Sep-02-20 11:23AM  
Sep-01-20 08:32AM  
Aug-06-20 06:30AM  
Aug-04-20 07:40AM  
Jul-28-20 08:13AM  
Jul-27-20 01:09PM  
Jul-20-20 06:30AM  
Jul-02-20 05:47AM  
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Matsuda KazukoChief Medical OfficerAug 23Option Exercise2.3060,000138,000322,996Aug 25 07:52 AM
IWAKI YUICHIPresident and CEOJul 09Option Exercise2.5439,583100,541966,933Jul 23 04:27 PM